Alliance A021806 (Pancreatic Cancer) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if it is better to give chemotherapy before or after surgery for pancreatic cancer. We want to know which approach gives people the best chance at a good outcome.

What is the Condition Being Studied?

Newly diagnosed pancreatic cancer

Who Can Participate in the Study?

Adults with pancreatic cancer who have not received treatment yet.

Age Group

What is Involved?

If you join this study, you will:
- Be randomly assigned (a fair 50/50 chance) to 1 of 2 treatment groups
-- One group will be treated with FOLFIRINOX chemotherapy for about 4 months, then have surgery, and receive FOLFIRINOX for about 2 months after surgery
-- The other group will have surgery first and then be treated with FOLFIRINOX for about 6 months after surgery
- Return to the clinic every 4 months for about 2 years after treatment is finished
- Receive phone calls every 6 months for about 6 years after treatment is finished

Study Details

Full Title
Alliance A021806: A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00107486
NCT: NCT04340141
Phase III
Enrollment Status
Open for Enrollment
Contact the Duke Recruitment Innovation Center